http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#Head http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#assertion http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#provenance http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#pubinfo http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#assertion http://purl.obolibrary.org/obo/DOID_14330 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_14330 http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01367 http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#association http://www.w3.org/2000/01/rdf-schema#label azilect rasagiline tablets is indicated for the treatment of the signs and symptoms of idiopathic parkinson s disease as initial monotherapy and as adjunct therapy to levodopa the effectiveness of azilect was demonstrated in patients with early parkinson s disease who were receiving azilect as monotherapy and who were not receiving any concomitant dopaminergic therapy the effectiveness of azilect as adjunct therapy was demonstrated in patients with parkinson s disease who were treated with levodopa azilect is indicated for the treatment of the signs and symptoms of idiopathic parkinson s disease as initial monotherapy and as adjunct therapy to levodopa 1 http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB01367 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#provenance http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#pubinfo http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#sig http://purl.org/nanopub/x/hasSignature KqHfWcFqxOPjCLlr8JVuD/Rc6XaU2+784tlFQJQwaSrJSX3r+xgty/DS31HABotG2ZKk8mJJMsdx/kwXwESTEUAp7OqDzKs0201hQC9xKPV8WAbjTY8XE7wPU1y1SMyssdPI+TZH0hYhf5FDLKW605qiFnxxgBs5y2sYTONMesA= http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk http://purl.org/dc/terms/created 2021-07-03T13:08:24.095+02:00 http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RACNyW-Z21sGeBNQAnssE-ot-aqR3LwWxjoq5aP708rgk https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs